The Nanotechnology Characterization Laboratory of the Frederick National Laboratory for Biomedical Research seeks parties interested in collaborative research to co-develop a ceramide and vinca alkaloid combination therapy for treatment of cancer.
The National Cancer Institute’s Pediatric Oncology Branch seeks partners interested in licensing or collaborative research to co-develop new immunotherapeutic agents based on chimeric antigen receptor (CARs) for the treatment of pediatric solid tumors.
Increased cyclin-dependent kinase 5 (CDK5) activity has recently emerged as a contributor to cancer progression. Researchers at the National Cancer Institute (NCI) and at the National Institute of Neurological Disorders and Stroke (NINDS) have shown that TP5, a small peptide inhibitor of CDK5 modified to facilitate passage through the blood brain barrier (BBB), has potential therapeutic benefit in glioblastoma (GBM) and colorectal carcinoma (CRC). NCI is seeking parties interested in co-developing and/or licensing TP5 for its use in the treatment of cancers with aberrant CDK5 expression as a mono-therapy or in an adjuvant setting with current standard-of-care.
The Protein Expression Laboratory at the National Cancer Institute in Frederick, MD is seeking statements of capability or interest from parties interested in collaborative research to further develop a platform technology for the targeted intra-cellular delivery of proteins using virus-like particles (VLPs).
Adoptive cell therapy uses cancer reactive T-cells to effectively treat cancer patients. Producing many persistent T-cells is critical for successful treatments. Researchers at the NCI seek licensing and/or co-development research collaborations for a novel method of producing effective T-cell populations using Akt inhibitors.
Researchers at the National Cancer Institute (NCI) developed five high-affinity, fully human monoclonal antibodies targeting FLT3. Chimeric antigen receptors (CARs) have also been constructed based on the antibodies identified and tested in animal models of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Natural products have long been considered a source of biologically active molecules against health disorders, including bone-loss related diseases. Cinnamolyoxy-mammeisin (CNM), can be isolated from Brazilian geopropolis and demonstrates anti-inflammatory activity. Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the Piracicaba Dental School, University of Campinas, Brazil, have shown CNM also demonstrates inhibition of oral bone loss. This invention is available for licensing and/or co-development opportunities.
Researchers at the National Cancer Institute (NCI) have developed a new format for expressing Chimeric Antigen Receptors (CARs) that is available for licensing and co-development. The inventors found that there was an increased therapeutic effect when using their proprietary (anti-glypican 3 [GPC3]) hYP7 antibody in this format. The novel technology is useful for improving CAR therapies to treat a range of cancers.
Inventors at the National Cancer Institute (NCI) have developed chimeric antigen receptors (CARs) that target two B cell surface antigens, CD19 and CD22, improving treatment of B-cell malignancies, such as acute lymphoblastic leukemia (ALL). NCI is actively seeking parties interested in licensing this invention to commercialist the bicistronic CAR construct targeting CD19 and CD22 for immunotherapy.
Researchers at the National Cancer Institute (NCI) have isolated two Glypican-1- (GPC1)- specific antibodies: the mouse monoclonal antibody HM2 that binds the C-lobe of GPC1 close to the cell surface, and the camel single domain antibody D4. The D4 single domain antibody (also called ‘nanobody’) has a high affinity for GPC1-positive tumor cells from both human and mouse origins. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.
NCI seeks partners to commercialize Griffithsin and Griffithsin tandemers as therapeutics for HIV infections that are resistant to native GRFT, specifically, additional studies on stability, toxicity, immunogenicity, and large-scale production.
Researchers at the National Cancer Institute (NCI) have isolated two high affinity anti-mesothelin single domain antibodies (also known as nanobodies), A101 and G8. These antibodies have been isolated from NCI’s newly developed camel single domain (VHH) libraries by phage display. The antibodies have a high affinity for mesothelin-positive tumor cells from both human and mouse origins. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.
Researchers at the NCI have developed immunologically active peptides of NGEP that activate cytotoxic lymphocytes to effectively kill prostate cancer cells. These peptides can be applied to multiple immunotherapy strategies to treat and prevent prostate cancer.
The National Cancer Institute, Surgery Branch, Tumor Immunology Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize T Cells Attacking Cancer: T Cell Receptors that Recognize the Tyrosinase Tumor Antigen
The National Cancer Institute's Laboratory of Experimental Immunology, Cancer Inflammation Program, seeks parties interested in collaborative research to co-develop, evaluate, or commercialize the use of certain cucurbatacins or withanolides in combination with pro-apoptotic agonists of TRAIL death receptors for cancer therapy.